GoAI
Get started
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc.

HOWL

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.8735

+$0.4423 · +102.57%

Aug 21, 4:00 PM ET

HOWL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

40

Expensive

Momentum

22

Weakening

Sentiment

31

Bearish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Daniel J. Hicklin
Listed since
Apr 30, 2021
Employees
39

Market position

Day range

Current $0.8735

52-week range

Current $0.8735

Open
$0.9832
Previous close
$0.4312
Volume
296.73M
469.26× average
Average volume
632.34K
Average daily volume
Market cap
42.45M USD
Beta
0.29
Market reference 1
50-day average
$0.3893
+124.40% above average
200-day average
$0.6582
+32.71% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-19.36M USD
P/E (TTM)
-1.19×
P/B (TTM)
2.61×
P/S (TTM)
2.02×
EV / EBITDA
0.36×
Earnings yield
-208.63%
Free cash flow yield
-206.81%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
86.43%
Operating margin
-121.78%
Net margin
-164.82%
Return on equity
-245.20%
Return on assets
-87.64%
Return on invested capital
-173.37%

Financial health

Debt / equity
0×
Current ratio
1.62×
Altman Z-score
-26.78
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends491%-1107%-2706%-4304%Gross margin, FY2022: 84.70%Gross margin, FY2023: 91.15%Gross margin, FY2024: 3.77%Operating margin, FY2022: -341.78%Operating margin, FY2023: -203.09%Operating margin, FY2024: -3904.19%Net margin, FY2022: -328.09%Net margin, FY2023: -187.37%Net margin, FY2024: -3740.85%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 84.70%. Gross margin FY2023 91.15%. Gross margin FY2024 3.77%. Operating margin FY2022 -341.78%. Operating margin FY2023 -203.09%. Operating margin FY2024 -3904.19%. Net margin FY2022 -328.09%. Net margin FY2023 -187.37%. Net margin FY2024 -3740.85%.

Income trends

Revenue

1.89M USD-90.55%

Operating income

−60.68M USD+17.55%

Net income

−60.82M USD+13.75%
Income trends across reported periods29.3M USD−8.12M USD−45.53M USD−82.95M USDRevenue, FY2022: 16.4M USDRevenue, FY2023: 19.94M USDRevenue, FY2024: 1.89M USDOperating income, FY2021: −50.09M USDOperating income, FY2022: −56.06M USDOperating income, FY2023: −40.5M USDOperating income, FY2024: −73.59M USDOperating income, FY2025: −60.68M USDNet income, FY2021: −49.98M USDNet income, FY2022: −53.81M USDNet income, FY2023: −37.37M USDNet income, FY2024: −70.52M USDNet income, FY2025: −60.82M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 16.4M USD. Revenue FY2023 19.94M USD. Revenue FY2024 1.89M USD. Operating income FY2021 −50.09M USD. Operating income FY2022 −56.06M USD. Operating income FY2023 −40.5M USD. Operating income FY2024 −73.59M USD. Operating income FY2025 −60.68M USD. Net income FY2021 −49.98M USD. Net income FY2022 −53.81M USD. Net income FY2023 −37.37M USD. Net income FY2024 −70.52M USD. Net income FY2025 −60.82M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—1.89M USD19.94M USD16.4M USD—
Cost of goods sold1.63M USD1.81M USD1.76M USD2.51M USD—
Gross profit−1.63M USD71K USD18.18M USD13.89M USD—
Research and development44.83M USD56.43M USD41.78M USD53.76M USD35.27M USD
Selling, general, and administrative15.85M USD19.05M USD18.67M USD21.5M USD14.82M USD
Operating expenses59.04M USD73.67M USD58.68M USD69.95M USD50.09M USD
Interest income3.11M USD6.67M USD7.42M USD1.91M USD104K USD
Interest expense5.27M USD4.66M USD3.14M USD——
Depreciation and amortization1.63M USD1.81M USD1.76M USD2.51M USD216K USD
Operating income−60.68M USD−73.59M USD−40.5M USD−56.06M USD−50.09M USD
Net income−60.82M USD−70.52M USD−37.37M USD−53.81M USD−49.98M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+20.54%
11 comparable reports
Latest EPS result
0.08
Estimate -0.28 · Beat by 128.57%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.13-0.1-0.32-0.55Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual -0.46, estimate -0.43, surprise -6.98%, Miss. Q2 2025, reported May 8, 2025: actual -0.4, estimate -0.44, surprise +9.09%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.4, estimate -0.5, surprise +20.00%, Beat. Q4 2025, reported Nov 4, 2025: actual -0.36, estimate -0.39, surprise +7.69%, Beat. Q1 2026, reported Mar 27, 2026: actual -0.2, estimate -0.34, surprise +41.18%, Beat. Q2 2026, reported May 7, 2026: actual -0.28, estimate -0.32, surprise +12.50%, Beat. Q3 2026, reported Jul 31, 2026: actual 0.08, estimate -0.28, surprise +128.57%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate -0.22, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates22.66M15.19M7.72M255KQ2 '24MissQ3 '24BeatQ4 '24EstimateQ1 '25EstimateQ2 '25EstimateQ1 '26EstimateQ3 '26MetQ4 '26Estimate
Q2 2024, reported May 3, 2024: actual 742K USD, estimate 1.46M USD, surprise -49.09%, Miss. Q3 2024, reported Aug 8, 2024: actual 1.14M USD, estimate 841.78K USD, surprise +35.78%, Beat. Q4 2024, reported Nov 7, 2024: actual —, estimate 709.32K USD, surprise —, Comparison unavailable. Q1 2025, reported Mar 11, 2025: actual —, estimate 301.59K USD, surprise —, Comparison unavailable. Q2 2025, reported May 8, 2025: actual —, estimate 375K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 27, 2026: actual —, estimate 300K USD, surprise —, Comparison unavailable. Q3 2026, reported Jul 31, 2026: actual 21M USD, estimate 21M USD, surprise 0.00%, Met estimate. Q4 2026, reported Nov 3, 2026: actual —, estimate 18.31M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$6.50

644.13% upside
Past 12 months12-month forecastHigh $12.00Average $6.50Low $1.00

Rating distribution

9 ratings
Strong buy00%
Buy889%
Hold111%
Sell00%
Strong sell00%

Recent analyst actions

4 institutions

HOWL news

gurufocus.com

HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) and Ambros Therapeutics, Inc. Upon clos

Read source
businesswire.com

HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) and Ambros Therapeutics, Inc. Upon closing of the proposed transaction,…

Read source
gurufocus.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC PR Newswire

Read source
invezz.com

Why Werewolf Therapeutics stock exploded higher and what comes next?

Werewolf Therapeutics (HOWL) stock exploded higher on Friday morning after management said the company has agreed to a definitive all-stock merger with Ambros Therapeutics. The combined company will pivot to focus on…

Read source
benzinga.com

One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was one of the market's biggest pre-market movers on Friday after announcing a merger with Ambros Therapeutics.

Read source
globenewswire.com

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement

WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agreement to combine…

Read source

HOWL peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding HOWL

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
308.52K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
121.55K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research HOWL

research.disclaimer